Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines

Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its pipeline and scale production in global markets.

Read the article at: https://www.biospace.com/article/releases/antheia-announces-73m-series-b-to-commercialize-synthetic-biology-platform-for-essential-medicines/